Ibrutinib

Last Updated: 02/24/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 4212 publications

Correction: Microsecond simulations to investigate the structural mechanism of super-resistant double mutations in BTK to the covalent inhibitor ibrutinib in multiple leukemia.

Correction: Microsecond simulations to investigate the structural mechanism of super-resistant double mutations in BTK to the covalent inhibitor ibrutinib in multiple leukemia.

Journal: Scientific reports
Published: January 20, 2026

Prolonged progression-free survival with zanubrutinib in relapsed/refractory CLL: an indirect treatment comparison versus other BTK inhibitors using multilevel network meta-regression.

Prolonged progression-free survival with zanubrutinib in relapsed/refractory CLL: an indirect treatment comparison versus other BTK inhibitors using multilevel network meta-regression.

Journal: Journal of medical economics
Published: January 19, 2026

Onychorrhexis and onychoschizia associated with ibrutinib therapy.

Onychorrhexis and onychoschizia associated with ibrutinib therapy.

Journal: JAAD case reports
Published: January 19, 2026

Chihara D, Steiner RE, Nair R, et al. Phase 2 trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomas. Blood Adv. 2025;9(7):1485-1491.

Chihara D, Steiner RE, Nair R, et al. Phase 2 trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomas. Blood Adv. 2025;9(7):1485-1491.

Journal: Blood advances
Published: January 06, 2026

A real-world study evaluating drug tolerability and health care resource use with acalabrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

A real-world study evaluating drug tolerability and health care resource use with acalabrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

Journal: Journal of medical economics
Published: December 27, 2025

Bilateral Nongranulomatous Anterior Uveitis with Macular Edema Associated with Ibrutinib Use: A Case Report.

Bilateral Nongranulomatous Anterior Uveitis with Macular Edema Associated with Ibrutinib Use: A Case Report.

Journal: Ocular immunology and inflammation
Published: December 23, 2025

New BTK Inhibitors May Combat Resistance in CLL.

New BTK Inhibitors May Combat Resistance in CLL.

Journal: Cancer discovery
Published: December 22, 2025

Patterns of Bruton's Tyrosine Kinase Inhibitor (BTKi) Usage in B-cell Lymphomas in India: A Questionnaire-Based Study.

Patterns of Bruton's Tyrosine Kinase Inhibitor (BTKi) Usage in B-cell Lymphomas in India: A Questionnaire-Based Study.

Journal: Cureus
Published: December 21, 2025

Ibrutinib in combination with rituximab, methotrexate, vincristine, and procarbazine (R-MVP/i) for newly diagnosed primary CNS lymphoma (PCNSL).

Ibrutinib in combination with rituximab, methotrexate, vincristine, and procarbazine (R-MVP/i) for newly diagnosed primary CNS lymphoma (PCNSL).

Journal: Neuro-oncology
Published: December 18, 2025

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.

Journal: The New England journal of medicine
Published: December 08, 2025

Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 07, 2025

Management of autoimmune hemolytic anemia.

Management of autoimmune hemolytic anemia.

Journal: Hematology. American Society of Hematology. Education Program
Published: December 05, 2025
Showing 1-12 of 4,212

Last Updated: 02/24/2026